Document jgG0D87ywqqRNjnpzJNQ00q02

dd Jan 21 WP Responsible WP0 DE/NL WP1 DE/NL Activities Coordination Preparation of Call for Evidence (including questionnaire and information document) in agreement between MS Call for Evidence (all MS and ECHA with news alerts and websites of all MS with Link to Helpdesk webpage) Preparation of Restriction option analysis document (all MS) WP2 NL RIME+ Dortmund 1st draft of restriction option analysis document (all MS) 2nd draft of restriction option analysis document (all MS) Finalisation of document, i.e. clarification of restriction options and scope (all MS) Restriction option analysis document to be uploaded on CIRCA (DE/ NL CA) RMOA-Conclusion, PACT-Update Drafting discussion paper Wordt vragenlijst + aanvulling 1e discussion paper Verwerken commentaren van NO, SE, DE, I&W en RIVM deskundige Topic 0 Topic 1 Topic 2 Topic 3 Topic 4 Regular activities Refine PFAS scope based on pragmatic aspects (a.o. coverage of PFAS subgroups by other legislations) Refine PFAS scope based on PFAS degradation patterns and hazard/risk profiles Refine PFAS scope definition based on essential uses Final Regulatory PFAS scope definition and support writing process WP3 DE/DK WP3 Env Coordination and alignment Environmental hazard assessment (different approach from draft content plan) and splitting into pre-assessment and assessment phase is not longer warranted) Identification degradation and biotransfirmation pathways (e.g. CATALOGIC) and further arrowhead substances WP4 DE/NL WP5 NO/DE WP6 SE/DE WP7 NL Overview analytical methods for PFAS. Develop 1) Text for sections on "Practicality and monitorability" in restriction report and annex of the restriction dossier (see also Appendix E.1 in PFHxA restriction dossier), and 2) Standalone report on analytical methods for PFASs. Work plan Tender bid published Consultant selected Restriction dossier text and standalone report finished Draft working plan Design template for collection of monitoring data Presentation of slide WP6 at RiME Meeting wieh NCSU Collect monitoring data - ENV Collect monitoring data - HUM RiME FEB-2021? HBM4EU Workshop Drafting dossier Share data / conclusions with other WPs (WP3, 4, 5) Include new relevant studies Scoping essential use Scoping impact assessment Baseline and restriction scenario(s) Economic impact assessment Environmental impact assessment Health impact assessment Assessment of other impacts Proportionality analysis Monthly meetings 2nd version questionnaire Draft of information document (DE/NL CA) Commenting round (all MS) Revision and draft of 3rd version of questionnaire and information document for WebEx (DE/NL CA) Detailed discussion of questionnaire and information document (all MS) Webex Final version (DE/ NL CA) Notification into PACT (DE/ NL CA) Discussion of responses received so far, data (all MS) Webex Decision on meetings with industry (all MS) Discussion of restriction scope and options (all MS) Webex Decision on which restriction options should be presented and discussed in RiME+ (all MS) Meetings with stakeholders and industry Presentation on RMOA for RiME Contributions of first drafts of document parts according to lead in work packages and sub-work packages (all MS) Merge of contributions, redrafting (DE/ NL CA) Redrafting by all MS Merge of contributions, redrafting (DE/ NL CA) Last redrafting by all MS Finalisation (DE/ NL CA) Commenting (by all other MS not part of group) Consideration of comments/if needed redrafting of document (DE/ NL CA in agreement with group) Webex meeting for initial discussing based on broad definition (NL, DE, SE, DK, NO, ECHA, COM) 1st discussion paper prepared by NL Face-to-face meeting (NL, DE, SE, DK, NO, ECHA, COM) based on discussion paper 2nd discussion paper prepared by NL (before RiME+) Discussion during RiME+ meeting Final discussion paper prepared by NL Overall Kick-off meeting 2021 second phase WP2 (2021, 2022) Weekly core-team meetings Monthly WP leader meeting Regular collaborating member state meetings Overall Align on RMOA needs with Work Package 1 (WP1) Study PFAS subgroups and coverage by other legislations , a.o. polymers, F-gasses, PPP, medicines Discuss with RIVM experts, Ministry I&W, and collaborating countries Write draft document Align with RIVM experts, Ministry I&W, and collaborating countries Finalise (informal) documentation and hand-over to WP1 Overall Ensure knowledge exchange with WP3, on CATABOL and CATALOGIC predictions Performance of literature study on PFAS degradation pathways, a.o. of short-chain PFAS, PFAS with ether group Ensure knowledge exchange with the RIVM project "PFAS in AV-rookgassen" Ensure knowledge exchange with WP3, on hazard and risk profiles Translate 2.1, 2.2, 2.3, 2.4 to refined PFAS scope definition and document Align with RIVM experts, Ministry I&W, and collaborating countries Overall Support WP7 on stock approach and the use of model chemicals as representatives of the scope definition Contact WP7 for definition of and clarification on 'essential use' Ensure alignment on 'Uses' with WP4, where relevant Translate in exclusions of (essential) use categories to adapted PFAS scope definition Align with RIVM experts, Ministry I&W, and collaborating countries (Informally) Document substantiation on in/or excluding PFAS subgroups from scope and decisions made Overall Align the final Annex XV writing with the different workpackages and collaborating countries Finalise the Regulatory PFAS scope definition that covers all input from topics 1, 2, and 3 Translate to legally correctly formulated substance definition, chemical definition, exemptions, derogations (Supprot) writing of draft texts for Annex XV Restriction proposal, where needed Reviewing of draft texts for Annex XV Restriction proposal written by other work packages Finalising of text(proposal)s for Annex XV Restriction proposal Kick-off meeting Joint HH/ENV progress meetings HH subgroup meetings ENV subgroup meetings Assessment of Env hazards of fluoropolymers, hydrofluorocarbons (input for WP2 and scope) Overview of Env hazards and available studies (also for long range transport etc) Meeting (WP3 and WP2): to discuss hazards supporting scope, to discuss lead substances/substance classes/arrowheads to be used as examples, to define and limit the (sub)groups of substances Further detailed assessment of PFAS/PFAS subgroups (including assessment of alternatives) Overview of transformation reactions forming basis of predictions; Understanding of PFAS and/or PFAS sub-groups being in and out of domain concerning predictions; Test if change of parameters lead to further arrowhead identification) Develop argumentation line for degradation and biotransformation pathways for PFAS; discussion if further predictions are needed Literature search to support argumentation line Start up, Develop generic information basis for all sub-uses, structure of the sub-use reports (by WP7) - DONE Kick-off meeting (Discussion of content of each sub-use to avoid overlaps and discussion of revision of list of sub-uses and discussion of ETH Zrich work) - DONE Start up sub uses, Project plan fine tuning for sub-uses (and if needed tendering for consultants) Progress meeting after CfE is closed to check sub-uses, decide on stakeholder meetings (i.e. via mail) Stakeholder Meetings per sub-use: Follow up on information from CfE and to address knowledge gaps Sub-use studies (including gap analysis) Progress meeting Progress meeting Final reports consultants (& feedback to WP2) Integration of information (including gap analysis) Additional studies (i.e. membranes, processing aids?) Additional stakeholder meetings? (digital?) Preparation of the Annexes to the restriction dossier Both human biomonitoring and environmental (bio)monitoring data Request to MSs to share monitoring data (incl. delivery of template) Share info on ongoing projects an monitoring data; (gg gg/gg gg/gg gg) Possibly remind about the request to MSs to share monitoring data (incl. delivery of template)? Workshop in March (date not decided yet) Continuous Literature review on `essential use' by RIVM Define criteria characterising `essential use' Sub-contracting stakeholder feedback study Solicit stakeholder feedback Consult PFAS project group regarding criteria and stakeholder feedback Decide on core criteria for essential use' used in dossier Apply criteria for determining essential and non-essential PFASs uses Assess substance properties (P, B, T, (M)) Develop conceptual cost-effectiveness analysis approach for proportionality assessment Define relevant impact categories Approach for assessing emissions and stock pollution Approach for monetising compliance costs per sector/use Decide on uses to include in impact assessment Formulate questions for call for evidence Decide for which uses or sectors of use market information + PFAS emissions to environment is required Call for tender market analysis Define baseline scenario Define restriction scenarios and derogations Call for evidence alternatives, analyse alternatives Collect relevant information on uses Categorise uses for market analysis Subcontract market analysis Conclude on cost estimates used in CEA Literature survey scientific and regulatory approaches to env. impact assessment for PBT/vPvB/PMT chemicals Decide how results from literature survey can be used in restriction dossier Decide on approach for assessing T Subcontract emission assessment per use category Emission and stock pollution assessment (per use category) Conclude on environmental impacts Literature survey scientific and regulatory approaches to health impact assessment for PBT/vPvB/ PMT chemicals Decide how results from literature survey can be used in restriction dossier Decide on approach for assessing T Subcontract emission assessment per use category Qualitative and semi-quantitative assessment of health impacts Conclude on (most relevant) health impacts Categorise and structure other impacts Subcontract assessment of other impacts per use category Qualitative and semi-quantitative assessment of other impacts Conclude on (most relevant) health impacts Define SEA scenarios corresponding to impact assessment Define benchmarks based on costs and discuss options for determining benchmarks based on effects Present CEA results Use information on health impacts to support proportionality assessment Sensitivity analysis starts Ends Remarks New deadline Status Ongoing May 2020 30-Apr-20 30-Mar-20 31-Mar-20 15-Apr-20 17-Apr-20 4/20/2020 24-Apr-20 27-Apr-20 4-May-20 30-Jul-20 Mid-November 2020 24-Aug-20 28-Sep-20 August/September 2020 20/21 October 2020 Oct-20 2-Oct-20 25-Sep-20 5-Oct-20 19-Oct-20 24-Sep-20 2-Oct-20 23-Oct-20 16-Oct-20 23-Oct-20 26-Oct-20 10-Nov-20 20-Nov-20 9-Nov-20 20-Nov-20 23 - 27 November 2020 1-Dec-20 1-Jan-21 4-Jan-21 June 2020 28-Jan-21 29-Jan-21 31-Aug-20 Sep-20 October 2020 October 2020 31-Dec-20 Complete Complete Complete Complete Complete Complete Complete Complete Complete Complete Complete Ongoing Ongoing Complete Complete In progress In progress 1-Feb-21 Not started Not started DE? Not started Not started Not started Not started Not started 31-mrt-21 Not started Complete Complete Complete Complete Complete Complete 1-Jan-21 30-Jun-22 , medicines 1-Jan-21 30-Jun-21 1-Feb-21 AS, PFAS with ether group 30-Jun-21 the scope definition 1-Feb-21 31-Dec-21 nd decisions made mptions, derogations 1-Oct-21 30-Jun-22 28 May 2020 Quarterly Monthly from Sept 2020 Monthly from Sept 2020 Ongoing Ongoing Ongoing Ongoing Started Started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Complete Started In progress In progress Not started 1-May-20 30-Jun-20 1-Jun-20 31-Jul-20 31-Aug-20 1-Aug-20 1-Aug-20 31-Oct-20 1-Sep-20 31-Dec-20 31-Oct-20 November/December 2020 Apr-21 1-Mar-21 31-Jul-21 1-Feb-21 31-Jul-21 1-Feb-21 30-Jun-21 1-Aug-21 31-Dec-21 July 2020 January 2021 April 2021 September 2021 1-May-20 1-Sep-20 1-Sep-20 15-Jan-21 15-Jan-21 15-Jan-21 4-Feb-21 1-Dec-20 1-Apr-21 1-Apr-21 30-Sep-21 1-May-20 1-May-20 1-Jul-20 1-Sep-20 1-Oct-20 15-Oct-20 15-Oct-20 ? 30-Jun-21 30-Jun-21 4-Feb-21 31-Mar-21 30-Sep-21 31-Dec-21 31-Dec-21 31-Jul-20 31-Jul-20 31-Jul-20 31-Dec-20 Not started In progress Not started Not started Complete Complete Complete Complete In progress In progress In progress Not started In progress Not started Not started Not started Complete In time Not started Not started Complete Complete Complete Not started In progress In progress Not started In progress Not started Not started Not started Complete In progress In progress In progress 1-Dec-20 1-Dec-20 1-Dec-20 1-Sep-20 1-Sep-20 1-Sep-20 1-Sep-20 1-Sep-20 1-Jan-21 1-Nov-20 1-Dec-20 1-Mar-21 1-Apr-21 1-Apr-21 1-Nov-20 1-Feb-21 1-Feb-21 1-Feb-21 1-Jul-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Feb-21 1-Sep-21 1-Sep-21 1-Sep-21 1-Sep-21 1-Sep-21 31-Dec-20 31-Jan-21 31-Jan-21 31-Jan-21 31-Jan-21 31-Jan-21 31-Jan-21 31-Jan-21 28-Feb-21 31-Dec-20 28-Feb-21 30-Apr-21 30-Apr-21 30-Apr-21 31-Mar-21 31-Jul-21 31-Jul-21 31-Jul-21 31-Jul-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 31-Aug-21 30-Nov-21 30-Nov-21 30-Nov-21 30-Nov-21 30-Nov-21 Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started Not started 2020 2021 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 .M M M M M M M M M M M M M M M M M M m, IIIII I M M M M M M M M MMMMMMM M M M MMMMMMM M 1 hE 2022 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 MM M M M MMMMMMMMM M M M % M MM M M M MM M M M ---- I --_-- | Remarks M (meeting), D (draft document), F (final document), X (activity ongoing) oo a WP Products 1 2 3 Preparation of Call for Evidence (including questionnaire WP1 and information document) in agreement between MS Call for Evidence (all MS and ECHA with news alerts and websites of all MS with Link to Helpdesk webpage) Preparation of Restriction option analysis document (all MS) RIME+ Dortmund 1st draft of restriction option analysis document (all MS) 2nd draft of restriction option analysis document (all MS) Finalisation of document, i.e. clarification of restriction options and scope (all MS) Restriction option analysis document to be uploaded on CIRCA (DE/ NL CA) RMOA-Conclusion, PACT-Update WP2 1st discussion paper prepared by NL Face-to-face meeting (NL, DE, SE, DK, NO, ECHA, COM) based on discussion paper 2nd discussion paper prepared by NL (before RiME+) Discussion during RiME+ meeting Final discussion paper prepared by NL Topic 1 Coverage of PFAS subgroups regulated by other legislations and conclusion other pragmatic aspects regarding PFAS scoping Topic 2 Conclusion on risk aspects and degratdation aspects regarding PFAS scoping Topic 3 Conclusion on essential use aspects regarding PFAS scoping Topic 4 WP3 Final contributions to writing restriction proposal regarding PFAS scoping Kick-Off Meeting [X = Pre-phase for environmental and human health hazard deadline assessment --> Overview of relevant hazards (besides according to persistence) and generation of draft lists of substances workplan] for assessment Identification of arrowhead substances, degradation and biotransformation pathways, known and so far identified chemical alternatives Add/Consider ECHA-database screening results Literature search for hazard data Consideration of relevant information from CfE (WP1) and surveys on uses (WP4) Co-ordination with sub-use WP4's on following up on hazard information for PFAS and alternatives Overview of relevant hazards Generation of list of PFASs (and/or precursors, metabolites, read across substances) with available hazard data Generation of list of chemical alternatives with available hazard data Meeting (WP3 and WP2): to discuss hazards supporting scope, to discuss lead substances/substance classes/arrowheads to be used as examples, to define and limit the (sub)groups of substances Meeting (WP3 and sub-WP4s): alignment on alternatives Addition of results from consultation and follow up in subWP4s, in relation to both PFAS and alternatives Identification of lead substances/substance groups to be assessed (draft list) Identification of alternatives to be assessed (draft list) Assessment phase --> Draft text for restriction proposal Refinement of draft lists for assessment Allocation of lead sustances/substance groups to MS Draft summaries for relevant endpoints (PFAS) Draft summaries for relevant endpoints (alternatives) Alignment of draft summaries and assessment Finalisation of assessment Start up, Develop generic information basis for all sub- WP4 uses, structure of the sub-use reports (by WP7) - DONE Kick-off meeting (Discussion of content of each sub-use to avoid overlaps and discussion of revision of list of sub- uses and discussion of ETH Zrich work) - DONE Start up sub uses, Project plan fine tuning for sub-uses (and if needed tendering for consultants) Progress meeting after CfE is closed to check sub-uses, decide on stakeholder meetings (i.e. via mail) WP5 WP6 WP7 Stakeholder Meetings per sub-use: Follow up on information from CfE and to address knowledge gaps Sub-use studies (including gap analysis) Progress meeting Progress meeting Final reports consultants WP4. A (firefighting foams) = Comm/ECHA WP4.B (SE, textiles) = Wood WP4.C (NL, FCM) = Exponent WP4.D (DE, consumer mixtures) WP4.E (DK, lubricants and construction) = Wood/Cowi WP4. F (SE, cosmetics) = Stockholm University WP4. G (NL, production) = RPA WP4. H (DE, chrome plating) WP4.J (NO, ski wax) = Wood WP4.M (NO, petroleum and mining) = Wood WP4.N (NL, medical) = gg gg WP4.P (NO, F-gases) = Exponent WP4.L (DE, Transportation) WP4. R (DE, Electronics) = Haskoning or RPA WP4. T (NL, waste) = Tauw or Ramboll Integration of information (including gap analysis) Additional studies Preparation of the Annexes to the restriction dossier Overview analytical methods (ch E7) Overview human and environmental monitoring data Scoping essential use Scoping impact assessment Baseline and restriction scenario(s) Economic impact assessment Environmental impact assessment Health impact assessment Assessment of other impacts Proportionality analysis 2020 4 5 6 7 8 9 10 11 12 1 Overall status begin Dec: not X finished yet, still in progress X Status: in progress X X Status: in progress X X Status: not started X Status: in progress X Status: in progress X Status: not started X Status: not started ? Status: not started X X Status: not started X Status: in progress X Status: not started X Status: not started X Status: in progress Status: started Status: not started Status: not started Status: not started draft draft draft draft draft ? draft draft draft draft draft draft draft 2 3 4 5 6 2021 7 8 9 10 11 X X X X X ? ? draft draft? draft 12 1 2 3 4 5 6 2022 7 8 9 X X 10 11 12 Column2 Complete In progress In time Not in time Not started Started Unknown